Shots: Domain to receive upfront, milestones, and royalties on sales from Boehringer Ingelheim The focus of the agreement is to discover & develop GPCRs, using Domain’s DTect-All and bioSens-All technology to characterize compounds for Neuropsychiatric Diseases GPCRs are receptors present in CNS, activates by binding with stimulus or ligand and regulates the functions of brain […]Read More
Tags : Domain Therapeutics
Latest Posts
Categories
Related Topics
AbbVie
Acceptance
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US